BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY) and Hycor Biomedical Sign Global Distribution Agreement


5/17/2012 9:51:44 AM

INDIANAPOLIS, May 16, 2012 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer of diagnostic products, and Roche today announced the signing of a global distribution agreement of KOVA® urinalysis products. As part of the agreement, Roche will distribute KOVA urinalysis plastics and controls products with its urinalysis tests and platforms worldwide for the next five years.

"Concurrent with our global leading position in invitro diagnostics, the expanded agreement with HYCOR emphasizes our commitment of bringing industry expertise in providing high-quality urinalysis products to health professionals at hospital laboratories," said Colin Brown, Head of Roche Professional Diagnostics.

KOVA urinalysis controls are used to validate the performance of urine chemistry test strips and readers and to help focus microscopic sediment analysis. KOVA urinalysis controls are part of a complete line of urinalysis products that include specially engineered Glasstic slides and high quality sample tubes.

"KOVA has been an industry-leader for more than 30 years, and we are pleased to partner with Roche to distribute this group of quality urinalysis products worldwide," said Dick Aderman, President and CEO, HYCOR. "This agreement allows us to expand our presence into an additional 85 markets, further underscoring the value it brings to the healthcare professionals and patients it serves."

All KOVA products are designed to make it easy and cost-efficient to standardize the urinalysis procedure by ensuring consistent sample preparation.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC, KOVA® and AUTOSTAT brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

SOURCE HYCOR Biomedical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES